This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Mar 1;36(7):631-632.

doi: 10.1200/JCO.2017.76.8770. Epub 2018 Jan 16.

Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

Conor E Steuer¹, Suresh S Ramalingam¹

Affiliations

PMID: 29337637
DOI: 10.1200/JCO.2017.76.8770

Editorial

Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

Conor E Steuer et al. J Clin Oncol. 2018.

. 2018 Mar 1;36(7):631-632.

doi: 10.1200/JCO.2017.76.8770. Epub 2018 Jan 16.

Authors

Conor E Steuer¹, Suresh S Ramalingam¹

Affiliation

¹ Conor E. Steuer and Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA.

PMID: 29337637
DOI: 10.1200/JCO.2017.76.8770

No abstract available

PubMed Disclaimer

Comment on

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. Rizvi H, et al. J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. J Clin Oncol. 2018. PMID: 29337640 Free PMC article.

Similar articles

Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
Mino-Kenudson M. Mino-Kenudson M. Cancer Cytopathol. 2017 Jul;125(7):521-528. doi: 10.1002/cncy.21873. Epub 2017 May 4. Cancer Cytopathol. 2017. PMID: 28472551 No abstract available.
Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z, Cheng G, Xu C, Wang W, Shao Y, Zhang Y. Song Z, et al. Lung Cancer. 2018 Apr;118:57-61. doi: 10.1016/j.lungcan.2018.02.004. Epub 2018 Feb 6. Lung Cancer. 2018. PMID: 29572003
Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
Dong J, Li B, Zhou Q, Huang D. Dong J, et al. J Evid Based Med. 2018 Nov;11(4):278-287. doi: 10.1111/jebm.12322. Epub 2018 Nov 16. J Evid Based Med. 2018. PMID: 30444051 Review.
Quantifying the benefit of non-small-cell lung cancer immunotherapy.
Ludmir EB, McCaw ZR, Grossberg AJ, Wei LJ, Fuller CD. Ludmir EB, et al. Lancet. 2019 Nov 23;394(10212):1904. doi: 10.1016/S0140-6736(19)32503-6. Lancet. 2019. PMID: 31777387 No abstract available.
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y. Takada K, et al. Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28. Clin Lung Cancer. 2018. PMID: 29153898 Review.

See all similar articles

Cited by

Parallelized Latent Dirichlet Allocation Provides a Novel Interpretability of Mutation Signatures in Cancer Genomes.
Matsutani T, Hamada M. Matsutani T, et al. Genes (Basel). 2020 Sep 25;11(10):1127. doi: 10.3390/genes11101127. Genes (Basel). 2020. PMID: 32992754 Free PMC article.
Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D, Chelvanambi M, Storkus WJ, Fecek RJ. Salem D, et al. Front Immunol. 2021 Mar 4;12:629519. doi: 10.3389/fimmu.2021.629519. eCollection 2021. Front Immunol. 2021. PMID: 33746966 Free PMC article. Review.
Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker for Breast Cancer.
Qiu J, Zhou T, Wang D, Hong W, Qian D, Meng X, Liu X. Qiu J, et al. Curr Genomics. 2023 Dec 20;24(5):307-329. doi: 10.2174/0113892029255941231014142050. Curr Genomics. 2023. PMID: 38235352 Free PMC article.
miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma.
Xue W, Wang Y, Xie Y, Yang C, Gong Z, Guan C, Wei C, Zhu C, Niu Z. Xue W, et al. Front Oncol. 2021 Jun 23;11:634841. doi: 10.3389/fonc.2021.634841. eCollection 2021. Front Oncol. 2021. PMID: 34262855 Free PMC article.
The prognostic and immune significance of PLBD1 in pan-cancer and its roles in proliferation and invasion of glioma.
Wei M, Zhou G, Chen L, Zhang Y, Ma W, Gao L, Gao G. Wei M, et al. J Cancer. 2024 May 20;15(12):3857-3872. doi: 10.7150/jca.96365. eCollection 2024. J Cancer. 2024. PMID: 38911364 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information